Use: Labeled indications
- INDICATIONS AND USAGE TIMOPTIC Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Full indications and usage US FDA label
INDICATIONS AND USAGE TIMOPTIC Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Contraindications
CONTRAINDICATIONS TIMOPTIC is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see WARNINGS]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see WARNINGS]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION TIMOPTIC Ophthalmic Solution is available in concentrations of 0.25 and 0.5%. The usual starting dose is one drop of TIMOPTIC 0.25% in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) twice a day.
Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with TIMOPTIC. If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s).
Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day. Dosages above one drop of TIMOPTIC 0.5% twice a day generally have not been shown to produce further reduction in intraocular pressure.
If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted. The concomitant use of two topical beta-adrenergic blocking agents is not recommended [see PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents].
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness of timolol maleate ophthalmic solution have been established when administered in pediatric patients aged 2 years and older. Use of timolol maleate ophthalmic solution in these children is supported by evidence from adequate and well controlled studies in children and adults. Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 2.5 mg/mL, 5 mg per mL, 5 mg/mL
- Opthalmic solution: 5 mg/g, 5 mg/mL
- Sterile ophthalmic solution: 5 mg/mL
- Ophthalmic sterile solution: 5 mg/mL
- W/v) ophthalmic solution: 5 mg/mL (0.5 %
Registered products in the Philippines
28 products registered with the Food and Drug Administration (FDA) Philippines list Timolol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products28
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Agua TimTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana Ophthalmics LLPIndia | Agua Visions TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-07 | Sep 5, 2029 | |
ElevexTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ambitech Biopharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-04 | Sep 5, 2029 | |
IntramolTimolol (as maleate) | 5 mg/mL Ophthalmic SolutionWhite LDPE dropper bottle with HDPE tamper evident screw cap and white LDPE dropper x 5 mL (Box of 1's) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Sensomed Phils., Inc.Importer: Ambica International Corporation | DRP-9405 | Feb 9, 2028 | |
IotimTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)Translucent LDPE Plastic Bottle x 5mL with insert cap assembly comprising of HDPE screw cap over a LDPE nozzle with LDPE dust cover (Box of 1's) | Rx | FDA LimitedIndia | Penta Labs Australia (Philippines) | DRP-7230 | Jun 19, 2027 | |
IsupresTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | I-Senz Medical Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-01 | Sep 5, 2029 | |
KhrizmololTimolol (as maleate) | 5 mg/mL (0.5 % w/v) Ophthalmic Solution (Eye Drops)10 mL -Capacity C White Opaque PP Dropper Bottle with cap x 5 mL (net content) (Box of 1's) | Rx | Merit Organics LimitedIndia | Khriz Pharma Trading, Inc. | DR-XY49716 | May 13, 2031 | |
LopresTimolol ( as maleate ) | 5 mg/mL (0.5% w/v ) Opthalmic Solution (Drops)5mL white translucent Low Density Polyethylene ( LDPE) Blow Fill Seal Container (BFS) with white High Density Polyethylene (HDPE) cap ( Box of 1's ) | Rx | Micro Labs. LimitedIndia | Brown & Burk Philippines Inc. | DRP-7281 | Aug 3, 2027 | |
LutimolTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL Low Density Polyethylene (LDPE) vial (Box of 1's) | Rx | Axa Parenterals LimitedIndia | Brady Pharma Inc. | DRP-9580 | Mar 5, 2031 | |
NoneTimolol Maleate | 0.5% w/v Sterile Ophthalmic SolutionWhite LDPE Dropper-tipped Bottle x 5mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | CELSUS PHARMACEUTICALS PHILS., INC. | DR-XY28847 | Aug 7, 2028 | |
NoneTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-03 | Sep 5, 2029 | |
NoneTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ambicare Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-05 | Sep 5, 2029 | |
NormopresTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic Sterile Solution (Eye Drops)5 mL net content in 10 mL LDPE dropper-tipped plastic bottle (Box of 1's) | Rx | EL Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY31154 | Aug 2, 2027 | |
OculolTimolol (as maleate) | 5 mg/mL (0.5%) Ophthalmic SolutionPlastic Droptainer Bottle x 5 mL (Box of 1's) | Rx | CENTAUR PHARMACEUTICALS PRIVATE LIMITEDIndia | AVANTMED INTERNATIONAL PHARMA INCImporter: STANGEN PHARMACEUTICALS PHILIPPINES INC | DR-XY38755 | Nov 18, 2028 | |
OCUPERTimolol Maleate | 5 mg/ mL (0.5%w/v) Ophthalmic Solution5 mL LDPE Plastic Bottle with Secondary Box (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Medilife Pharma, Inc. | DRP-233 | Jun 21, 2031 | |
OcutimTimolol maleate | 5mg/g (0.5 % w/v) Opthalmic SolutionLDPE vial x 5 mL (Box of 1’s) | Rx | East African (India) OverseasIndia | Airlife International Trading Corporation | DRP-18055 | Apr 30, 2031 | |
OptaluzTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-02 | Sep 5, 2029 | |
OptamolTimolol (As Maleate) | 2.5 mg/mL (0.25% w/v) Ophthalmic Solution (Eye Drops)LDPE Plastic container x 5 mL Box of 1's | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY36653 | Sep 16, 2029 | |
OptimolTimolol ( as maleate) | 5 mg / mL (0.5% w/v) Opthalmic Solution (Drops)LDPE Dropper Bottle with Blue Cap x 5 mL (Box of 1's) | Rx | Laboratorios Ashford Lda.China | Marrion Pharma Inc. | DR-XY35195 | Dec 3, 2034 | |
OptinovaTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution (Drops)5 mL HDPE Vial fitted with Screw Cap (Box of 1's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Medinova Pharmaceutical Inc. | DRP-11804 | May 6, 2027 | |
TimabakTimolol Maleate | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL LDPE Bottle with HDPE Cap (Box of 1's) | Rx | ExcelvisionFrance | STADA Philippines Inc.Trader: Laboratoires Thea | DR-XY37200 | Dec 10, 2029 | |
TimoCareTimolol Maleate | 5 mg/ mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Plastic Bottle with Secondary Box (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Rizal | Sensorycare Pharma Co.Trader: Medilife Pharma, Inc. | DRP-233-03 | Jun 21, 2031 | |
Timol-PTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ophtha Pharma Traders Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499-06 | Sep 5, 2029 | |
Timolet ODTimolol (as maleate) | 5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution (Drops)5 mL LDPE sterile dropper bottle, plugged with 13 mm. LDPE sterile plug and capped with 13 mm white, mm opaque HDPE pilfer proof sterile cap for dropper bottle (Box of 1's) | Rx | Sun Pharmaceutical Medicare LimitedIndia | Sun Pharma Philippines, Inc. | DRP-11016 | Jan 3, 2032 | |
TimophilTimolol (as maleate) | 5mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops) | Rx | Skymap Pharmaceuticals Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-17726 | Feb 23, 2031 | |
TimoptolTimolol maleate | 5 mg/mL (0.5% w/v)LDPE Type-6 container x 5 mL (Box of 1's) | Rx | Santen Pharmaceutical Co., Ltd. (Noto Plant)Japan | Importer: Santen Philippines Inc. | DR-X6980 | Aug 2, 2031 | |
TimosaphTimolol (As Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)White HDPE Dropper Bottle with Close nozzle and single pilfer proof ring Cap x 5 mL (net content) (Box of 1's) | Rx | Health Biotech Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd | DRP-13632 | Mar 21, 2028 | |
TimostalTimolol (as Maleate) | 5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ophthamed Pharma Corp.,Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-5499 | Sep 5, 2029 | |
TomololTimolol (As Maleate) | 5 mg per mL Ophthalmic Solution10 mL PET Bottle with Tamper-Evident Cap (Box of 1's) | Rx | Joint Stock Company "Farmak"Ukraine | Suhitas Pharmaceuticals, Inc. | DRP-12880 | Oct 24, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS As with many topically applied ophthalmic drugs, this drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate [see CONTRAINDICATIONS].
Cardiac Failure Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition of beta-adrenergic receptor blockade may precipitate more severe failure. In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure.
At the first sign or symptom of cardiac failure, TIMOPTIC should be discontinued. Obstructive Pulmonary Disease Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which TIMOPTIC is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blockers, including TIMOPTIC.
Major Surgery The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures.
Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.
If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents.
Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia. Thyrotoxicosis Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Although TIMOPTIC used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with TIMOPTIC and epinephrine has been reported occasionally. Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and TIMOPTIC should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.
The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium antagonists: Caution should be used in the coadministration of beta-adrenergic blocking agents, such as TIMOPTIC, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension.
In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. CYP2D6 inhibitors: Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.
Clonidine: Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. There have been no reports of exacerbation of rebound hypertension with ophthalmic timolol maleate. Injectable epinephrine: [see PRECAUTIONS, General, Anaphylaxis].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
CYP2D6 inhibitors: Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The most frequently reported adverse experiences have been burning and stinging upon instillation (approximately one in eight patients). The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations: Body as a Whole Headache, asthenia/fatigue, and chest pain.
Cardiovascular Bradycardia, arrhythmia, hypotension, hypertension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud's phenomenon, and cold hands and feet. Digestive Nausea, diarrhea, dyspepsia, anorexia, and dry mouth.
Immunologic Systemic lupus erythematosus. Nervous System/Psychiatric Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss.
Skin Alopecia and psoriasiform rash or exacerbation of psoriasis. Hypersensitivity Signs and symptoms of systemic allergic reactions, including anaphylaxis, angioedema, urticaria, and localized and generalized rash. Respiratory Bronchospasm (predominantly in patients with preexisting bronchospastic disease), respiratory failure, dyspnea, nasal congestion, cough and upper respiratory infections.
Endocrine Masked symptoms of hypoglycemia in diabetic patients [see WARNINGS]. Special Senses Signs and symptoms of ocular irritation including conjunctivitis, blepharitis, keratitis, ocular pain, discharge (e.g., crusting), foreign body sensation, itching and tearing, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; choroidal detachment following filtration surgery [see PRECAUTIONS, General]; and tinnitus.
Urogenital Retroperitoneal fibrosis, decreased libido, impotence, and Peyronie's disease. The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Body as a Whole: Extremity pain, decreased exercise tolerance, weight loss; Cardiovascular: Worsening of arterial insufficiency, vasodilatation; Digestive: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; Hematologic: Nonthrombocytopenic purpura; thrombocytopenic purpura, agranulocytosis; Endocrine: Hyperglycemia, hypoglycemia; Skin: Pruritus, skin irritation, increased pigmentation, sweating; Musculoskeletal: Arthralgia; Nervous System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics; Respiratory: Rales, bronchial obstruction; Urogenital: Urination difficulties.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects - Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring.
Doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.
There are no adequate and well-controlled studies in pregnant women. TIMOPTIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from TIMOPTIC in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Mechanism of action
Mechanism of Action Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease.
In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity.
Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous. TIMOPTIC Ophthalmic Solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss.
The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. The onset of reduction in intraocular pressure following administration of TIMOPTIC can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose.
Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC is well maintained. The precise mechanism of the ocular hypotensive action of TIMOPTIC is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation.
However, in some studies a slight increase in outflow facility was also observed.
US FDA labelPharmacokinetics
Pharmacokinetics (US label) US FDA label
Pharmacokinetics In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Timolol Eye Drops 0.5%, 5 mL Bottle | ₱210.00–₱360.00Reference ₱281.50 | per bottle | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Timolol (as maleate) |
| PNF listing | Eye Drops Solution: 0.5%, 5 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Timoptic · Bausch & Lomb Incorporated [US FDA-approved label, version 11, April 30, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45ac65b3-19f7-4f33-aebf-cadd3daa4bf1
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .